What is the evidence for oral or intra-articular administration of collagen derivatives in patients with osteoarthritis for joint pain reduction and physical function improvement?
AMSTAR Rating
Summary
Patient Population:
A total of 35 randomized controlled trials (RCTs) encompassing 3,165 patients were identified. To strictly eliminate small-study overestimation biases, 10 trials with extremely small samples (<20 patients per arm) were excluded from primary analyses. The main analysis for pain was based on 25 RCTs involving n = 2,856 patients with clinical osteoarthritis (predominantly knee or hip cohorts). The average age across trials typically spanned between 50 and 60 years old, tracking chronic, symptomatic joint degeneration.
Intervention:
Oral or intra-articular administration of various structural collagen derivatives. Dosing and sub-type formulations tracked across the literature included oral collagen hydrolysates (typically 10 to 12 g daily), oral undenatured type II collagen (UC-II, typically 40 mg daily), oral collagen peptides, oral gelatin (10 g daily), or localized intra-articular polymerized type I/II atelocollagen injections.
Comparison:
Inactive matched oral placebos, active standard-of-care pharmaceutical options (such as nonsteroidal anti-inflammatory drugs [NSAIDs] or oral acetaminophen), or alternative localized joint therapies (including intra-articular hyaluronic acid injections).
Outcome:
Random-effects meta-analysis demonstrated that collagen derivatives exert small-to-moderate, statistically significant beneficial impacts compared to controls.
For the primary outcome of joint pain, analysis revealed a significant benefit (Standardized Mean Difference [SMD] = -0.35; 95% CI, -0.48 to -0.22; moderate certainty), translating to an average drop of 8.5 mm on a standard 100-mm visual analog scale. (NOTE: MCID ranges from 8.4-19.9mnm in the literature: https://www.ncbi.nlm.nih.gov/books/NBK447534/)
Significant clinical functionality improvements were similarly proven (SMD = -0.31; 95% CI, -0.41 to -0.22; high certainty).
Subgroup evaluations revealed no significant differences in therapeutic efficacy between alternative formulations (p = 0.25).
Safety mapping confirmed excellent tolerability, with no increased risk for all-cause study withdrawal (Risk Ratio [RR] = 1.09; 95% CI, 0.91 to 1.31) or general adverse events (RR = 1.02; 95% CI, 0.88 to 1.17). Trial sequential analysis (TSA) verified that current data volumes crossed established boundaries for definitive medical benefit, confirming these conclusions are robust.
Guideline Recommendations
Outcomes Assessed
- Benefit
- Harm
- Inconclusive
Pain
VAS 8.5mm reduction on 100mm scale
Function
General inventories of function
Safety
No increased risk
Relevant Clinical Info
Lugo JP, Saiyed ZM, Lane NE. Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study. Nutr J. 2016;15:14.
Lugo et al. (2016) was a prominent, rigorous multi-center double-blind RCT heavily relied upon in the meta-analysis, investigating an active sample of 191 patients with symptomatic knee osteoarthritis. Participants were randomized to receive either a daily oral dose of 40 mg undenatured type II collagen (UC-II), a standard combination of glucosamine and chondroitin, or an identical placebo over a 180-day protocol. The trial robustly demonstrated that the UC-II group achieved statistically superior, durable pain reduction and functional joint scores compared to both the placebo and the active nutraceutical control arms, providing a primary clinical anchor for the biological efficacy of oral undenatured collagen derivatives.
Participant Information
The sample size was 2856
There were 25 studies used.
